Advertisement


Jonathan E. Rosenberg, MD, on Urothelial Cancer: New Conclusions About Durvalumab Plus Olaparib

2022 ASCO Genitourinary Cancers Symposium

Advertisement

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II findings from the BAYOU trial, which studied durvalumab in combination with olaparib for first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma. Because secondary analyses indicated a potential progression-free survival benefit with this combination, there may be a role for PARP inhibitors in the treatment of advanced disease with homologous recombination repair mutation (Abstract 437).



Related Videos

Kidney Cancer
Immunotherapy

Axel Bex, MD, PhD, on Renal Cell Carcinoma: New Findings From the NeoAvAx Trial on Avelumab and Axitinib

Axel Bex, MD, PhD, of The Netherlands Cancer Institute, discusses an efficacy, safety, and biomarker analysis of neoadjuvant avelumab and axitinib in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (Abstract 289).

Prostate Cancer

Xin Gao, MD, on Prostate Cancer: Early-Phase Results on Bavdegalutamide

Xin Gao, MD, of Massachusetts General Hospital, discusses phase I/II findings on bavdegalutamide, an androgen receptor protein degrader, which showed clinical activity in heavily pretreated patients with metastatic castration-resistant prostate cancer who received one to two prior novel hormonal agents.

Prostate Cancer

Karim Fizazi, MD, PhD, on Prostate Cancer: Early Results From the CYPIDES Trial of ODM-208

Karim Fizazi, PhD, MD, of Gustave Roussy and University of Paris-Saclay, discusses results from a first-in-human phase I/II trial, which showed that administering ODM-208—an oral, nonsteroidal inhibitor of the enzyme CYP11A1—to men with metastatic castration-resistant prostate cancer who were pretreated with abiraterone/enzalutamide and taxanes was effective in blocking the production of steroid hormones. It also showed antitumor activity, especially in men with AR mutation–positive cancers.

Prostate Cancer

Axel S. Merseburger, MD, on Prostate Cancer: New Data From the PRESIDE Trial on Enzalutamide, Docetaxel, and Prednisolone

Axel S. Merseburger, MD, of the University Hospital Schleswig-Holstein, discusses results from a phase IIIb study of chemotherapy-naive patients with metastatic castration-resistant prostate cancer who have been treated with docetaxel plus prednisolone and experienced disease progression on enzalutamide. The data suggest that continued enzalutamide plus docetaxel improved progression-free survival compared with placebo plus docetaxel (Abstract 15).

Bladder Cancer

Massimo Di Maio, MD, on Urothelial Cancer: Data on Niraparib and Best Supportive Care as Maintenance Therapy

Massimo Di Maio, MD, of the University of Turin, discusses the Meet-URO12 study, which showed that maintenance niraparib plus best supportive care (BSC) did not prolong progression-free survival, compared with BSC alone, among patients with urothelial cancer that did not progress after first-line platinum-based chemotherapy.

Advertisement

Advertisement



Advertisement